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SUMMARY
Objective: To assess the prevalence of metabolic syndrome and its components in HIV 
infected individuals assisted in a specialized health center in a municipality in the state of 
Santa Catarina, Brazil. Methods: Cross-sectional study comprising 249 individuals (130 
men and 119 women), aged 18 to 73 years. Metabolic syndrome was defined according to 
the National Cholesterol Education Program, as recommended by the Brazilian Society 
of Cardiology. Results: Among the individuals who participated in the study, 20.9% had 
metabolic syndrome - 18.5% of the men and 23.5% of the women, with no statistical as-
sociation between genders. Twenty seven percent of the individuals had two components 
of the syndrome. Components most frequently found were those related to lipid profile 
(low HDL-cholesterol and high triglycerides), followed by elevated waist-circumference, 
altered blood pressure and altered fasting blood glucose. There was a significant associa-
tion between gender and elevated waist-circumference. Conclusion: The prevalence of 
metabolic syndrome found in this study possibly reflects the quality of the health ser-
vices delivered. We highlight the importance of investigating the presence of metabolic 
syndrome among HIV-infected populations, thus contributing for their survival.
Keywords: Acquired immunodeficiency syndrome; metabolic syndrome x nutritional 
status.
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INTRODUCTION
Metabolic changes, such as peripheral insulin resistance, 
diabetes mellitus, changes in lipid metabolism and body 
fat distribution, lactic acidosis, osteopenia, and others can 
oen be observed in HIV-infected individuals and they 
are reported to be associated with antiretroviral therapy1-5. 
Since these abnormalities include mostly glucose metabo-
lism disorders and dyslipidemias, they oen meet metabo-
lic syndrome (MS) criteria6-8.
MS can be defined as a disorder characterized by the 
presence of cardiovascular risk factors related to central fat 
accumulation and to increased insulin resistance, as well 
as an increased intimal media thickness with atheroma 
formation and a consequent occurrence of cardiovascular 
disease-related morbidity and mortality7,9.
MS has been reported as more prevalent among HIV- 
infected individuals than in general population7,10,11,17. 
The higher frequency of metabolic changes increases dia-
betes mellitus and atherosclerotic disease risk among HIV- 
infected patients, and the presence of MS is related to in-
creased mortality from coronary artery disease, regardless 
of factors such as age, gender, blood cholesterol, physical 
activity and smoking12.
These facts are of great importance, especially consi-
dering the increased life expectancy and the reduced mor-
tality from AIDS achieved by the antiretroviral therapy 
currently used and the distribution of free medication13. 
Furthermore, MS diagnosis can be useful for decision-
making in primary health care concerning cardiovascular 
disease prevention7.
Thus, the objective of this study was to assess the pre-
valence of MS and its components in HIV-infected patients 
assisted in an infectious disease-specialized health care cen-
ter in a municipality in the state of Santa Catarina, Brazil.
METHODS
All patients evaluated in a specialized health care center in 
a municipality in the state of Santa Catarina, Brazil, from 
August 2007 to January 2008, were invited to participate 
in the study. All HIV-infected patients aged 18 and older 
were included in the sample regardless of being on highly 
active antiretroviral therapy (HAART) or not, as long as 
they accepted to participate in the study. Those who had 
any physical disabilities precluding the anthropometric as-
sessment (waist circumference) or did not have the results 
of blood biochemical tests were excluded. The study pro-
tocol was approved by the Ethics in Research Committee 
of Universidade do Vale do Itajaí (Univali) and all subjects 
gave written informed consent.
The cut-o values proposed by the NCEP-ATPIII (Na-
tional Cholesterol Education Program – Adult Treatment 
Panel III) were used to diagnose MS. They advocate com-
bining at least three of the following components: waist cir-
cumference >102cm for males and 88cm for females; fas-
ting blood glucose≥110mg/dL; triglycerides ≥ 150mg/dL; 
HDL-cholesterol ≤ 40mg/dL for males and ≤ 50mg/dL 
for females; systolic blood pressure ≥ 130mmHg; diasto-
lic blood pressure≥ 80mmHg9. Thus, the variables waist 
circumference, serum HDL-cholesterol and triglycerides 
level, fasting blood glucose, and blood pressure (systolic 
and diastolic) were collected. Waist circumference was 
measured with an inelastic tape measure before medical 
appointments.
As the patients seen at that health center usually un-
dergo routine biochemical tests assessing their lipid profile 
in a frequency ranging from two to six months, the HDL-
cholesterol and triglyceride levels recorded on the closest 
date to the anthropometric assessment were collected. 
Systolic and diastolic blood pressure levels were checked 
by a skilled nursing professional before medical appoint-
ments as well. Data regarding HAART use were further 
collected from medical records3.
Descriptive statistics was used according to the distri-
buition of the variable: for variables with a normal distri-
bution, occurrence measures and mean and standard de-
viation values were shown; for non-parametric variables, 
lowest, highest and median values were shown. Student’s 
t test and Mann-Whitney test were used to compare me-
ans, according to the distribuition of variables. The asso-
ciation between MS components and gender was tested 
by Pearson’s chi-square test, and the association between 
HAART use and the presence of MS was tested by mul-
tivariate logistic regression analysis using the soware 
Statistica (version 6.0)14. Dierences were considered 
significant at the level of p<0.05.
RESULTS
This study included 249 patients, 52.2% being males 
(n±=±130) and 47.8% females (n±=±119); ages ranged from 
17 to 73 years. Mean age was 42.03±±±9.56 years for ma-
les and 40.12±±±9.75 for females. In the study population, 
86.7% were on HAART (n±=±216) and 6.8% were on sta-
tins (n±=±17). See Table±1 for the main characteristics of 
patients regarding the MS components. Males had signifi-
cantly higher values for waist circumference, triglycerides, 
fasting blood glucose and diastolic blood pressure compa-
red with females.
Among the assessed individuals, 20.9% had MS (n±=±52), 
with 18.5% being males (n±=±24) and 23.5% females (n±=±28), 
with no association between genders (chi-square±=±0.96; 
p±=±0.32). Patient distribution according to the number of 
MS components is shown in Box 1, whereas the frequen-
cies, according to gender and each syndrome component 
are found in Table±2. A statistically significant association 
was found only for gender and elevated waist circumferen-
ce. The components with the highest frequencies were re-
lated to the lipid profile (low HDL-cholesterol and high 
triglycerides), followed by elevated waist circumference 
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and altered blood pressure and fasting blood glucose. Hi-
ghly active antiretroviral therapy was not associated with 
MS, even aer adjustments for age and gender (odds ra-
tio=0.64; p=0.41; confidence interval=0.22-1.86).
Santa Maria, RS. In the current study, a prevalence of 20.9% 
of MS was found in HIV-infected adults seen at the only 
specialized health center in the municipality.
Despite the importance of MS, most Brazilian stud-
ies have assessed specific populations, with those assessing 
this problem at a population level being sparse. Thus, it is 
di cult to evaluate the relevance of MS prevalence found 
in the current study compared to healthy populations. The 
only population-based study of which we know indicated 
a 29.8% MS prevalence in Vitória (ES) residents, with no 
gender dierence, this being a superior result compared to 
the current study20.
In addition, although the prevalence of MS found in 
our population is similar to that found in a Brazilian study 
with a healthy population and higher than that found in 
a study with HIV-infected Brazilian individuals, we must 
stress that 26.9% of the study subjects had two components 
of the syndrome, being at risk for developing it.
In this study, the main components responsible for MS 
diagnosis were those related to the subjects’ lipid profile (low 
HDL-cholesterol and high triglycerides) and elevated waist 
circumference. Population studies assessing MS in HIV-in-
fected individuals indicate a dierent participation of its com-
ponents in the diagnosis of the syndrome. Mondy et al.15 ob-
served the major contributors to MS in French patients were 
altered fasting blood glucose and high blood pressure. In a 
Danish cohort of HIV-infected patients, elevated blood pres-
sure was found in 51% of the subjects, high blood triglycer-
ides in 44%, reduced HDL-cholesterol levels in 39%, abdomi-
nal obesity in 21%, and altered blood fasting glucose in 16%8.





Waist circumference (cm) 85 (65-110) 82 (61-117) 84 (61-117) < 0.01
HDL-cholesterol (mg/dL) 41 (13-90) 49 (22-79) 45 (13-90) < 0.001
Triglycerides (mg/dL) 146 (56-1266) 120 (55-590) 137 (55-1266) < 0.01
Fasting blood glucose (mg/dL) 90 (53-298) 86 (55-128) 88 (53-298) < 0.01
Systolic blood pressure (mmHg) 120 (80-200) 120 (88-190) 120 (80-200) ns
Diastolic blood pressure (mmHg) 80 (40-110) 80 (40-140) 80 (40-140) < 0.05
* Values expressed in medians (lowest-highest).







Box 1 – Distribution of HIV-infected patients according 
to the number of metabolic syndrome components. Santa 
Catarina, Brazil, 2007-2008
DISCUSSION
Although there is evidence of higher MS prevalence in 
HIV-infected patients and consequent increased risk for 
cardiovascular diseases, Brazilian studies assessing this 
syndrome magnitude in this population are only a few.
A number of international studies point out prevalences 
ranging from 7.4% to 27%7,8,15,16. Few Brazilian studies on 
this subject have been reported. Silva et al.17 assessed HIV-in-
fected patients in São Paulo, SP, and found a 13% prevalence 
of MS in patients on HAART and 12% among treatment-
naïve patients. Diehl et al.18 found a 36% MS prevalence in 
HIV-infected patients from Londrina, PR, whereas Troian 
et al.19 observed 38.2% in HIV-infected individuals from 
Components
Gender
Total % (n) p
Male % (n) Female % (n)
Elevated waist circumference 27.7 (36) 57.1 (68) 41.8 (104) < 0.001
Low HDL-cholesterol 46.9 (61) 53.8 (64) 50.2 (125) ns
High triglycerides 49.2 (64) 37.8 (45) 43.8 (109) ns
Altered blood glucose 9.2 (12) 5.0 (6) 7.2 (18) ns
Altered blood pressure 17.0 (22) 18.5 (22) 17.7 (44) ns
Table 2 – Frequency of metabolic syndrome components among HIV-infected patients. Santa Catarina, Brazil, 2007-2008
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In a Brazilian study conducted by Diehl et al.18, preva-
lences of 68% of reduced HDL-cholesterol, 55% of high 
blood triglycerides, 32% of high blood pressure, 23% of al-
tered fasting blood glucose, and 17% of elevated waist cir-
cumference were found; the prevalence of elevated waist 
circumference was significantly higher in females, as we 
found in our study. Leite and Sampaio5, by assessing pa-
tients who were on antiretroviral therapy in a university 
hospital in Rio de Janeiro, found a 70% prevalence of re-
duced HDL-cholesterol and 48.1% of altered triglycerides. 
In a study by Silva et al.17, the MS component most fre-
quently found in patients on HAART was high triglycer-
ides, followed by reduced HDL-cholesterol, whereas treat-
ment-naïve patients had reduced HDL-cholesterol more 
frequently, followed by high triglycerides.
Although there are many reports about an increase 
in metabolic changes in HIV-positive patients on anti-
retroviral therapy, this association is somewhat contro-
versial4,5,7,15-17,21 In our study, this association could not 
be demonstrated. We must consider that as the majority 
of patients was on HAART, this might have contributed 
to the outcome. Our sample might not have had enough 
power to indicate statistically significant dierences, con-
sidering the confidence interval found. In addition, we can 
mention as a limitation to our study its cross-sectional de-
sign, not allowing us to know how long the subjects with 
the diagnosis of MS really have had the syndrome and 
whether it results from drug therapy or have already ex-
isted previously to the diagnosis. Higher body mass index, 
waist-hip ratio, diastolic blood pressure and triglycerides, 
as well as reduced HDL-cholesterol early in HAART treat-
ment are reported to be significantly associated with the 
development of MS16.
Despite the reduced number of Latin-American and 
Brazilian studies about MS in HIV-infected individuals, 
the lower prevalences of the syndrome and its compo-
nents found in the current study might reflect the quality 
of health services locally delivered. Further studies are re-
quired to define the role metabolic complications can play 
in the course and prognosis of the disease, stressing their 
role as cardiovascular risk factors.
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